The Asia
Pacific Newborn Screening Market, by Products (Hearing Screening Devices,
Mass Spectrometer, Pulse Oximetry, and Assay Kits and Reagents), by Test Type
(Phenylketonuria (PKU), Critical Congenital Heart Defect (CCHD), Hearing
Screening, Sickle Cell Disease, Maple Syrup Urine Disease (MSUD), Thyroid
Disorder, Biotinidase Deficiency (BTD), and Others), by End User (Hospitals,
Maternity & Specialty Clinics, and Diagnostic Centers), was valued at US$
190.2 million in 2018 and is projected to exhibit a CAGR of 12.7%, during the
forecast period (2018 - 2026).
Government bodies are focusing on
initiatives to create awareness about newborn screening tests and are offering
free screening services in some regions and rising funding. Furthermore,
various government programs and legislations are also creating a conducive environment
for growth of the Asia pacific newborn screening market. For instance, a
newborn screening program was recommended by the World Health Organization
(WHO) to safeguard the health of children across the globe. Under this program,
numerous policies and initiatives have taken by the Human Services Secretary’s
Advisory Committee on Heritable Disorders in Newborns and Children (SACHDNC)
and the U.S. Department of Health, advocacy groups such as the March of Dimes
and Japan’s Society of Obstetrics and Gynecology (JSOG) and UK (PEACH). The
World Health Organization (WHO) is focusing on allocation of necessary
resources as an additional investment of US$ 0.20 cents per person, which can
save 2 of every 3 newborns in low and middle income countries by 2030.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2546
Browse 32 Market Data Tables and 40
Figures spread through 193 Pages and in-depth TOC on "Asia Pacific Newborn
Screening Market, by Products (Hearing Screening Devices, Mass Spectrometer,
Pulse Oximetry, and Assay Kits and Reagents), by Test Type (Phenylketonuria
(PKU), Critical Congenital Heart Defect (CCHD), Hearing Screening, Sickle Cell
Disease, Maple Syrup Urine Disease (MSUD), Thyroid Disorder, Biotinidase
Deficiency (BTD), and Others), by End User (Hospitals, Maternity &
Specialty Clinics, and Diagnostic Centers)
- Forecast to 2026"
Development of cost-effective newborn
screening devices is a challenging aspect in emerging countries. Manufacturers
could focus on emerging countries such as China, India, Brazil, and South
Africa for development of newborn screening devices, owing to relatively high
birth rates. Furthermore, manufacturers could focus on developing novel newborn
screening methodology, which will be affordable, as the healthcare
infrastructure is rapidly enhancing in Asia pacific countries and the
regulatory scenario is also favorable for growth of the market. In November
2018, GE Healthcare collaborated with Beyond Zero Initiative to improve access
to quality and affordable primary healthcare services in Kisumu County.
Browse
Research Report: https://www.coherentmarketinsights.com/market-insight/asia-pacific-newborn-screening-market-2546
Key
Takeaways of the Asia Pacific Newborn Screening Market:
The Asia Pacific newborn screening
market is expected to expand at a CAGR of 12.7% during the forecast period
(2018 – 2026), owing to increasing government support to deploy efficient and
cost-effective newborn screening devices
Among product type, assay kits and
reagents segment is expected to witness maximum growth, owing to engagement of
key players in offering superior quality reagents to screen disorders and
deficiencies in newborn
Various national governments in the
region are actively promoting the newborn hearing tests, which is expected to
fuel demand for hearing screening in the near future. For instance, according
to the International Journal of Preventative Health 2015 report, the Department
of Prevention of Communication Disorders of All India Institute of Speech and
Hearing (AIISH) located in the Southern India conducts infant screening for
hearing disorder on regular basis in different hospitals using Behavioral
Observational Audiometry, Otoacoustic Emissions (OAE) screening, and administering
High Risk Register (HRR).
Major players operating in the Asia
Pacific newborn screening market include Medtronic plc, Agilent Technologies,
Waters Technologies Corporation, AB SCIEX, Bio-Rad Laboratories, Covidien PLC,
GE Life Sciences, Masimo Corporation, Natus Medical Inc., PerkinElmer Inc.,
Trivitron Healthcare Pvt. Ltd., and ZenTech S.A.
Buy-Now
this research report: https://www.coherentmarketinsights.com/insight/buy-now/2546
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN
: +050-5539-1737
No comments:
Post a Comment